If FDA could veto patents … Brazil shows how that might work
This article was originally published in Scrip
Executive Summary
Authorities in Brazil are ploughing ahead with draft legislation to entrench the right of Brazilian medicines regulator to reject patents on medicinal products and processes. This runs counter to legal opinions received by the Brazilian government (and backed by R&D-based industry) that the regulator – ANVISA – should be more or less removed from the patent granting process.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.